ADC Therapeutics Reports Q4, 2025 Preliminary ZYNLONTA Net Product Revenue Of ~$22M, ~$73M, Respectively

Benzinga · 4d ago

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program.